January 19, 2022, 07:17 GMT —
Proposals related to finding a cure for a rare inherited retinal disease are due by March 31, 2022.
SPRINGFIELD, MA, UNITED STATES /EINPresswire.com/ — The Choroideremia Research Foundation (CRF) is pleased to welcome proposal submissions for the 3rd Annual Randy Wheelock Research Award. The award designation recognizes emerging scientists and research professionals working on choroideremia (CHM) or related vision loss issues. Eligible recipients will be either doctoral or post-doctoral candidates and professionals, and awards will be granted in the amount of $50,000.
Introduced in 2020, the Randy Wheelock Award celebrates the decades-long advocacy of its namesake to find treatment or a cure for CHM. As CRF’s Chief Advisor for Research and Therapy Development, Randy was an integral part of the organization’s achievements over the years. He collaborated with researchers and other rare disease groups to leverage assets and scientific knowledge in search of treatment options and a cure for CHM.
Randy became actively involved with CRF in 2007 following the diagnosis of his son with CHM. As a devoted husband and father, Randy changed gears and worked tirelessly to learn all that he could about the retina and Choroideremia. He was a businessman who turned himself into a self-trained scientist who would not take “no” for an answer.
Previous award recipients include:
Kim Edwards (2020), Cellular and Molecular Pathology program at University of Wisconsin-Madison
“Identifying the Function of REP-1 Protein in Retina (RPE/Photoreceptors) and Non-Retina Tissues.”
Dr. Cynthia Qian (2021), Department of Ophthalmology, Centre hospitalier universitaire Sainte-Justine
“Characterizing the phenotypical findings in female carriers with confirmed CHM mutation using multimodal imaging and functional test.”
For more information about applying, please visit the Apply for Funding page on curechm.org/research/. Proposals are due March 31, 2022.
Choroideremia (CHM) is a rare inherited form of blindness affecting approximately 1 in 50,000 people. Due to its x-linked inheritance pattern males are most severely affected with females usually experiencing much milder visual impairment. Symptoms begin in early childhood with night blindness and restriction of visual field being the earliest noticeable effects, eventually progressing to complete blindness. An estimated 6,000 people in the United States and 10,000 in the European Union are impacted by Choroideremia. There are currently no approved treatments for Choroideremia.
About the Choroideremia Research Foundation Inc.
The Choroideremia Research Foundation was founded in 2000 as an international fundraising and patient advocacy organization to stimulate research on CHM. Since its inception, the CRF has provided over $2.5 million in research awards and is the largest financial supporter of CHM research worldwide. Research funded by the CRF has led to the development of a CHM animal model, the pre-clinical production of gene therapy vectors currently in clinical trials, and the CRF Biobank which stores tissue and stem cell samples donated by CHM patients. For more information, visit www.curechm.org